Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

NCT02747043 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL: ABP 798
BIOLOGICAL: Rituximab

Sponsor

Amgen